featured
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Without ASCT for Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Blood Cancer J 2024 May 29;14(1)87, BA Derman, J Cooperrider, J Rosenblatt, DE Avigan, M Rampurwala, D Barnidge, A Major, T Karrison, K Jiang, A Ramsland, T Kubicki, AJ JakubowiakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.